MCP server for Yeelight home metadata and management workflows
Server has 4 tools with basic schemas and descriptions, but significant gaps limit production readiness. Tool naming follows verb_noun convention (list_*, execute_*), which is good. However, descriptions are minimal (10-50 chars for most), parameter descriptions are sparse or missing, and output schemas are not documented. The execute_action tool accepts a complex nested 'request' object with undescribed sub-properties, violating the parameter-description rule. No error handling guidance, no pagination support for list tools, and no indication of which operations are idempotent or safe to retry. Tool composition is reasonable (separate list vs execute), but parameter naming could be more explicit (e.g., 'task_id' vs 'task').
Execute a metadata task action with context and payload
List all task groups
List all houses for the current user
List metadata tasks with optional filtering by group, query, task ID, or limit
Descriptions too short (10-50 chars) for LLM tool selection. list_houses and list_groups lack context on when to call them vs each other. Minimum 50-100 chars recommended.
execute_action's 'request' parameter has nested properties (task, action, context, payload, options) but sub-properties lack descriptions. LLMs cannot infer what 'context' object structure is required or what 'payload' should contain.
No output schemas documented for any tool. LLMs cannot plan downstream calls or extract required fields (e.g., does list_tasks return task_id, task_name, group?). Breaks tool chaining.
Inferred effective spec: 2026-07-28+.
| Scored | Grade | Overall | Spec posture | Rubric |
|---|---|---|---|---|
| 2026-09-23 | D | 55 | 2026-07-28+ | v2 |
list_tasks accepts 'limit' parameter but no pagination guidance (offset, cursor, total_count). Large result sets will blow context window. No indication of default limit or max.
execute_action is marked WRITE but no dry-run, confirmation, or idempotency guidance. Agents cannot safely retry on ambiguous failures without risking duplicate side effects.